Aardvark Therapeutics, Inc. ( (AARD) ) has released its Q3 earnings. Here is a breakdown of the information Aardvark Therapeutics, Inc. presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to treat metabolic diseases, with a particular emphasis on conditions like Prader-Willi Syndrome and obesity.
In its third-quarter 2025 earnings report, Aardvark Therapeutics highlighted significant progress in its clinical programs and financial standing. The company announced a strategic alignment with the FDA to lower the age of eligibility for its Phase 3 trial of ARD-101, aimed at treating hyperphagia in Prader-Willi Syndrome, and shared promising preclinical data for ARD-201 at ObesityWeek 2025.
Key financial metrics from the report include a cash position of $126.4 million, which is expected to support operations into 2027. The company reported increased research and development expenses, primarily due to the advancement of ARD-101, and a net loss of $16.3 million for the quarter. Aardvark also noted the commencement of enrollment for its HERO Open Label Extension trial and the initiation of clinical trial sites in Australia.
The company’s strategic announcements include plans to advance ARD-201 into two Phase 2 trials, POWER and STRENGTH, to further explore its potential in managing obesity. The preclinical data presented suggests ARD-201 could play a significant role in glucose control and weight management, especially after the discontinuation of GLP-1RA therapies.
Looking forward, Aardvark Therapeutics remains focused on its clinical development programs, with anticipated milestones including the release of topline data from the Phase 3 HERO trial in 2026 and preliminary data from the Phase 2 POWER trial in the second half of 2026. The company continues to explore innovative solutions for metabolic diseases, aiming to address unmet needs in the therapeutic landscape.